ReviewBiomedicines2023
The Future of Precision Medicine in the Cure of Alzheimer's Disease.
Review in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Clinical prediction models using artificial intelligence approaches in dementia.Aging clinical and experimental research · 2025Pooled it
- The Role of GFAP in Post-Mortem Analysis of Traumatic Brain Injury: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Impact of Recording Conditions and Feature Fusion on Dementia Classification Using Spectral, Entropy, and Complexity EEG Features.Entropy (Basel, Switzerland) · 2026Article
- Autopsy findings in Alzheimer's disease clinical trial participants demonstrate a high frequency of off-target coexisting pathologic features.The journal of prevention of Alzheimer's disease · 2026Article
- Beyond Amyloid: Hippocampal Atrophy as a Prognostic Marker in Amyloid-Negative Subjective Cognitive Decline.Journal of clinical neurology (Seoul, Korea) · 2026Article
- Cognitive heterogeneity in mild cognitive impairment due to Alzheimer's disease pathology.Neural regeneration research · 2026Article
- Neuroprotective effects of ursodeoxycholic acid in Parkinson's disease and Alzheimer's disease.Neuroprotection (Chichester, England) · 2026Review
- From Molecular Networks to Medicines: Targeting Complexity in Alzheimer's Disease (AD) Therapy.Molecular neurobiology · 2026Review
- Baseline FDG-PET Brain hypometabolism as a predictive biomarker of cognitive decline and Alzheimer's disease risk.The journal of nutrition, health & aging · 2026Article
- Bridging the gaps in alzheimer's disease: a comprehensive review of current and emerging therapies.Inflammopharmacology · 2026Review
- Review
- Review
- Ginkgolide as a Promising Multi-Target Therapeutic for Alzheimer's Disease: Targeting ApoE4 and Beyond.Current pharmaceutical design · 2026Article
- EVs from Stem Cells Improve Mitochondrial Dysfunction in Neuronal Disorders.Molecular neurobiology · 2025Review
- Move to Remember: The Role of Physical Activity and Exercise in Preserving and Enhancing Cognitive Function in Aging-A Narrative Review.Geriatrics (Basel, Switzerland) · 2025Review
- Unconventional Non-rodent Models in Neurological Research: Exploring New Paths to Translational Insights.Journal of molecular neuroscience : MN · 2025Review
- Targeting NLRP3 inflammasome with curcumin: mechanisms and therapeutic promise in chronic inflammation.Inflammopharmacology · 2025Review
- Revolutionizing Alzheimer's Detection: Immune-Related Gene Biomarkers as Non-Invasive Predictors.Molecular neurobiology · 2025Article
- Resveratrol as a Therapeutic Agent in Alzheimer's Disease: Evidence from Clinical Studies.Nutrients · 2025Review
- Considerations for informing precision psychiatry in eating disorders: Foundations for future practice.Journal of eating disorders · 2025Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This decade has seen the beginning of ground-breaking conceptual shifts in the research of Alzheimer's disease (AD), which acknowledges risk elements and the evolving wide spectrum of complicated underlying pathophysiology among the range of diverse neurodegenerative diseases. Significant improvements in diagnosis, treatments, and mitigation of AD are likely to result from the development and application of a comprehensive approach to precision medicine (PM), as is the case with several other diseases. This strategy will probably be based on the achievements made in more sophisticated research areas, including cancer. PM will require the direct integration of neurology, neuroscience, and psychiatry into a paradigm of the healthcare field that turns away from the isolated method. PM is biomarker-guided treatment at a systems level that incorporates findings of the thorough pathophysiology of neurodegenerative disorders as well as methodological developments. Comprehensive examination and categorization of interrelated and convergent disease processes, an explanation of the genomic and epigenetic drivers, a description of the spatial and temporal paths of natural history, biological markers, and risk markers, as well as aspects about the regulation, and the ethical, governmental, and sociocultural repercussions of findings at a subclinical level all require clarification and realistic execution. Advances toward a comprehensive systems-based approach to PM may finally usher in a new era of scientific and technical achievement that will help to end the complications of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.